Cannabidiol for the Treatment of Pediatric Epilepsy (Expanded Access/Compassionate Use Protocol)

Trial Profile

Cannabidiol for the Treatment of Pediatric Epilepsy (Expanded Access/Compassionate Use Protocol)

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 May 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 01 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Dec 2015 Results of 162 patients from 11 sites in the US published in The Lancet Neurology, according to a GW Pharmaceuticals media release.
    • 24 Dec 2015 Results of 162 patients included in the safety and tolerability analysis and 137 patients included in the efficacy analysis from 11 independent epilepsy centres in the US published in a GW Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top